A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy

This randomized, double-blind, placebo-controlled study will evaluate the safety and
efficacy of RoActemra/Actemra (tocilizumab) in patients with ankylosing spondylitis who have
had an inadequate response to previous TNF antagonist therapy. Patients will be randomized
to receive RoActemra/Actemra at a dose of either 8 mg/kg or 4mg/kg intravenously (iv) or
placebo every 4 weeks for 24 weeks. The double-blind treatment period will be followed by
open-label treatment with RoActemra/Actemra 8 mg/kg iv every 4 weeks until Week 104 for all
patients. Anticipated time on study treatment is 104 weeks.